Dog owners report improvement after Sn-117m treatment

Abstract

OBJECTIVE: To evaluate owner-reported satisfaction and perceived effects of Sn-117m radiosynoviorthesis (RSO) for canine osteoarthritis (OA). METHODS: An anonymous multicenter online survey was distributed between December 2024 and February 2025 to owners whose dogs received Sn-117m RSO for OA. Owners rated changes in pain and OA interference with daily activity before and after treatment and overall satisfaction. They also rated the influence of cost, clinical outcome, sedation/anesthesia, and other factors on satisfaction. RESULTS: Complete responses were obtained from 168 of 397 owners (42.3%). Overall, 63.1% (106 of 168) reported being very satisfied or satisfied. Osteoarthritis interference with daily activity improved in 71.5% (118 of 165) of dogs, remained unchanged in 27.3% (45 of 165), and worsened in 1.2% (2 of 165). Three dogs had no OA interference at baseline. The median improvement was +1 category (IQR, 0 to 2; range, -1 to +5). Among those that improved, the median change was +2 categories (range, +1 to +5). Perceived pain improved in 78.6% (132 of 168) after the first treatment, 82.9% (29 of 35) after the second, and 83% (5 of 6) after the third. Among 35 dogs receiving multiple treatments, 81% of owners reported comparable or greater improvement after subsequent treatments. Treatment-related concerns were reported by 6.5% of owners. Clinical outcome was rated the most influential factor in owner satisfaction (68% very influential). CONCLUSIONS: Owners reported satisfaction with Sn-117m RSO and perceived meaningful, repeatable improvements in pain and function. CLINICAL RELEVANCE: Sn-117m RSO produced perceived clinically important improvements in canine OA, with satisfaction driven primarily by clinical outcome rather than cost, sedation/anesthesia, or other concerns.